Fastest Growing & Innovative Companies
PBN would like to thank all those who attended last evening's sold out Fastest G ...
By PBN Staff
By PBN Staff
WASHINGTON, D.C. – The National Cancer Institute recently announced a scientific framework for advancing research on pancreatic cancer, as directed under the Recalcitrant Cancer Research Act of 2012.
U.S. Sen. Sheldon Whitehouse, D-RI, and U.S. Representatives Anna G. Eshoo, D-CA, and Leonard Lance, R-NJ, – the authors of the legislation – joined Senate Health, Education, Labor, and Pensions (HELP) Committee Chairman Tom Harkin in welcoming the framework.
“Too many lives have been cut short by pancreatic cancer, which remains difficult both to detect and to treat,” said Whitehouse. “This step forward will give new hope to those facing this terrible disease. I am grateful to the tireless cancer awareness advocates whose steadfastness helped turn this idea into law.”
“We applaud the National Cancer Institute and Dr. Varmus for releasing this crucial report. It provides specific recommendations that when fully implemented will advance national efforts to improve pancreatic cancer patient outcomes,” said Julie Fleshman, president and CEO for the Pancreatic Cancer Action Network. “We look forward to working with the NCI, our colleagues in the pancreatic cancer community and Congress to implement the recommendations and ensure that the final action plan includes all of the provisions of the statute.”
The Recalcitrant Cancer Research Act directs the National Cancer Institute, part of the National Institutes of Health, to work with federal and nonfederal representatives to develop scientific frameworks for assessing and advancing research on cancers with five-year survival rates below 50 percent.